Neuromodulation最新文献

英文中文

Best Practice Guidelines for Neuromodulation in Pain Management: Insight From the Neuromodulation Society of Australia and New Zealand 疼痛管理中神经调节的最佳实践指南：来自澳大利亚和新西兰神经调节协会的见解。

IF 3.5 3区医学 Q2 CLINICAL NEUROLOGY

Neuromodulation

Pub Date : 2026-01-01 DOI: 10.1016/j.neurom.2025.03.080

Tim Ho MBBS, MSc , Michelle O’Brien MBBS, M.Med. , Richard Sullivan MBChB , Jane Standen MBBS , Andrew D.H. Weiss MD, MSc , Dan Bates BMed, BSc , John Salmon MBBS , Nick Christelis MBBCh , James Yu MD , Murray Taverner MBBS , Marc Russo MBBS DA(UK)

Objectives

The Neuromodulation Society of Australia and New Zealand (NSANZ) developed evidence-based best practice guidelines for spinal cord stimulation (SCS) in chronic pain management. The primary objective was to provide clear guidance to support evidence-informed care across Australia and New Zealand, with a focus on patient selection, procedural techniques, and complication management.

Materials and Methods

A systematic literature review was conducted using Medline, EMBASE, Trip Pro, and Google Scholar, covering publications from 2010 to July 2024. A total of 283 studies and relevant clinical guidelines were included on the basis of level 1B evidence or strong expert consensus, consistent with the Grading of Recommendations Assessment, Development, and Evaluation criteria. Clinical questions were developed using the Population, Intervention, Comparison, and Outcome framework, and a Delphi process was used to achieve consensus among NSANZ board members.

Results

The guidelines provide comprehensive recommendations on patient selection, preparation, procedural techniques, postimplantation care, and complication management. Additional guidance is included on training standards, quality improvement processes, and the importance of multidisciplinary collaboration. Key recommendations emphasize optimizing patient selection, enhancing procedural safety, and improving treatment outcomes.

Conclusions

These guidelines offer practical, evidence-informed recommendations for the safe and effective use of SCS in chronic pain management. By promoting consistency, transparency, and collaborative care, they aim to guide clinical decision-making and support the delivery of evidence-informed neuromodulation services across Australia and New Zealand.

目的：澳大利亚和新西兰神经调节学会（NSANZ）制定了脊髓刺激（SCS）治疗慢性疼痛的循证最佳实践指南。主要目标是提供明确的指导，以支持澳大利亚和新西兰的循证护理，重点是患者选择，手术技术和并发症管理。材料与方法：采用Medline、EMBASE、Trip Pro、谷歌Scholar等软件进行系统文献综述，涵盖2010年至2024年7月发表的文献。根据1B级证据或强有力的专家共识，与分级推荐评估、发展和评估标准一致，共纳入283项研究和相关临床指南。使用人口、干预、比较和结果框架制定临床问题，并使用德尔菲过程在NSANZ董事会成员中达成共识。结果：该指南对患者的选择、准备、手术技术、种植后护理和并发症处理提供了全面的建议。额外的指导包括培训标准、质量改进过程和多学科合作的重要性。主要建议强调优化患者选择，加强程序安全性和改善治疗结果。结论：这些指南为安全有效地使用SCS治疗慢性疼痛提供了实用的、循证的建议。通过促进一致性、透明度和协作性护理，他们旨在指导临床决策，并支持在澳大利亚和新西兰提供循证神经调节服务。

{"title":"Best Practice Guidelines for Neuromodulation in Pain Management: Insight From the Neuromodulation Society of Australia and New Zealand","authors":"Tim Ho MBBS, MSc , Michelle O’Brien MBBS, M.Med. , Richard Sullivan MBChB , Jane Standen MBBS , Andrew D.H. Weiss MD, MSc , Dan Bates BMed, BSc , John Salmon MBBS , Nick Christelis MBBCh , James Yu MD , Murray Taverner MBBS , Marc Russo MBBS DA(UK)","doi":"10.1016/j.neurom.2025.03.080","DOIUrl":"10.1016/j.neurom.2025.03.080","url":null,"abstract":"<div><h3>Objectives</h3><div>The Neuromodulation Society of Australia and New Zealand (NSANZ) developed evidence-based best practice guidelines for spinal cord stimulation (SCS) in chronic pain management. The primary objective was to provide clear guidance to support evidence-informed care across Australia and New Zealand, with a focus on patient selection, procedural techniques, and complication management.</div></div><div><h3>Materials and Methods</h3><div>A systematic literature review was conducted using Medline, EMBASE, Trip Pro, and Google Scholar, covering publications from 2010 to July 2024. A total of 283 studies and relevant clinical guidelines were included on the basis of level 1B evidence or strong expert consensus, consistent with the Grading of Recommendations Assessment, Development, and Evaluation criteria. Clinical questions were developed using the Population, Intervention, Comparison, and Outcome framework, and a Delphi process was used to achieve consensus among NSANZ board members.</div></div><div><h3>Results</h3><div>The guidelines provide comprehensive recommendations on patient selection, preparation, procedural techniques, postimplantation care, and complication management. Additional guidance is included on training standards, quality improvement processes, and the importance of multidisciplinary collaboration. Key recommendations emphasize optimizing patient selection, enhancing procedural safety, and improving treatment outcomes.</div></div><div><h3>Conclusions</h3><div>These guidelines offer practical, evidence-informed recommendations for the safe and effective use of SCS in chronic pain management. By promoting consistency, transparency, and collaborative care, they aim to guide clinical decision-making and support the delivery of evidence-informed neuromodulation services across Australia and New Zealand.</div></div>","PeriodicalId":19152,"journal":{"name":"Neuromodulation","volume":"29 1","pages":"Pages 1-14"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144160647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of High-Frequency 10-kHz Spinal Cord Stimulation in the Treatment of Persistent Spinal Pain Syndrome Type 2: A Systematic Review 使用高频10khz脊髓刺激治疗2型持续性脊柱疼痛综合征：系统综述。

IF 3.5 3区医学 Q2 CLINICAL NEUROLOGY

Neuromodulation

Pub Date : 2026-01-01 DOI: 10.1016/j.neurom.2025.08.417

Saiganesh Ravikumar MD, MPH , Brandon Stevens MS , Te'Amrat Mehreteab , Michael Erdek MD, MA

Objectives

In 2015, 10-kHz high-frequency (10-kHz) spinal cord stimulation (SCS) received Food and Drug Administration approval to treat persistent spinal pain syndrome type 2 (PSPS-2). The outcomes of 10-kHz SCS on PSPS-2 have not been systematically reviewed. We systematically reviewed the relevant literature and hypothesized that 10-kHz SCS is safe and effective in managing pain in patients with PSPS-2.

Materials and Methods

PUBMED and EMBASE data bases were searched with the query ((spinal cord stimulator) OR (spinal cord stimulation) OR (SCS)) AND (pain) AND ((10 khz) OR (10-khz) OR (HF10) OR (HF-10)) on April 24, 2024.

Results

The search produced 636 nonduplicate articles. After applying the inclusion/exclusion criteria, nine studies were selected. Seven studies reported the percentage passing 10-kHz SCS trial, and the weighted average based on the number of patients was 87.3% success rate overall. Three studies measured overall pain on the visual analog scale (VAS), and six measured VAS back and leg separately. The weighted average for VAS overall, back, and leg was 8.1 (preoperation), 4.7 (postoperation); 7.0 (preoperation), 2.0 (postoperation); and 5.7 (preoperation), 1.6 (postoperation), respectively. Two studies evaluated the Beck Depression Index, and the weighted average was 23.8 (preoperation) and 14.0 (postoperation). Three studies evaluated the Oswestry Disability Index (ODI), and the weighted average was 48.3 (preoperation) and 30.6 (postoperation). Two studies compared burst stimulation with 10-kHz SCS, and both found no difference in back pain scores, whereas both studies found greater improvement in leg pain in the burst groups. Two studies compared low-frequency SCS with 10-kHz SCS, and both studies found no significant difference in VAS or ODI scores between the two treatments. There were no reported unanticipated adverse device effects across the studies.

Conclusion

For many patients with refractory PSPS-2, 10-kHz SCS is a safe, effective treatment, but there is a lack of evidence of its superiority to burst or traditional SCS.

2015年，10 khz高频（10 khz）脊髓刺激（SCS）获得美国食品和药物管理局（fda）批准，用于治疗2型持续性脊柱疼痛综合征（PSPS-2）。10khz SCS对pps -2的效果尚未系统回顾。我们系统地回顾了相关文献，并假设10khz SCS在治疗PSPS-2患者疼痛方面是安全有效的。材料和方法：于2024年4月24日检索PUBMED和EMBASE数据库，检索条件为((spinal cord stimulator) OR (spinal cord stimulation) OR (SCS) and (pain) and ((10khz) OR (10khz) OR （HF10) OR (HF-10)）。结果：搜索产生了636篇不重复的文章。应用纳入/排除标准后，选择了9项研究。7项研究报告了10-kHz SCS试验的通过率，基于患者数量的加权平均成功率为87.3%。3项研究用视觉模拟量表（VAS）测量总体疼痛，6项研究分别测量背部和腿部的VAS。VAS总体、背部和腿部加权平均值分别为8.1（术前）、4.7（术后）；7.0（术前），2.0（术后）；术前5.7分，术后1.6分。两项研究评估了贝克抑郁指数，加权平均值分别为23.8（术前）和14.0（术后）。3项研究评估了Oswestry残疾指数（ODI），加权平均值分别为术前48.3和术后30.6。两项研究比较了爆发刺激和10 khz SCS，都发现背部疼痛评分没有差异，而两项研究都发现爆发组在腿部疼痛方面有更大的改善。两项研究比较了低频SCS和10khz SCS，两项研究均发现两种治疗之间的VAS或ODI评分无显著差异。在所有的研究中都没有发现意想不到的不良反应。结论：对于许多难治性PSPS-2患者，10khz SCS是一种安全、有效的治疗方法，但缺乏证据表明其优于burst或传统SCS。

{"title":"Use of High-Frequency 10-kHz Spinal Cord Stimulation in the Treatment of Persistent Spinal Pain Syndrome Type 2: A Systematic Review","authors":"Saiganesh Ravikumar MD, MPH , Brandon Stevens MS , Te'Amrat Mehreteab , Michael Erdek MD, MA","doi":"10.1016/j.neurom.2025.08.417","DOIUrl":"10.1016/j.neurom.2025.08.417","url":null,"abstract":"<div><h3>Objectives</h3><div>In 2015, 10-kHz high-frequency (10-kHz) spinal cord stimulation (SCS) received Food and Drug Administration approval to treat persistent spinal pain syndrome type 2 (PSPS-2). The outcomes of 10-kHz SCS on PSPS-2 have not been systematically reviewed. We systematically reviewed the relevant literature and hypothesized that 10-kHz SCS is safe and effective in managing pain in patients with PSPS-2.</div></div><div><h3>Materials and Methods</h3><div>PUBMED and EMBASE data bases were searched with the query ((spinal cord stimulator) OR (spinal cord stimulation) OR (SCS)) AND (pain) AND ((10 khz) OR (10-khz) OR (HF10) OR (HF-10)) on April 24, 2024.</div></div><div><h3>Results</h3><div>The search produced 636 nonduplicate articles. After applying the inclusion/exclusion criteria, nine studies were selected. Seven studies reported the percentage passing 10-kHz SCS trial, and the weighted average based on the number of patients was 87.3% success rate overall. Three studies measured overall pain on the visual analog scale (VAS), and six measured VAS back and leg separately. The weighted average for VAS overall, back, and leg was 8.1 (preoperation), 4.7 (postoperation); 7.0 (preoperation), 2.0 (postoperation); and 5.7 (preoperation), 1.6 (postoperation), respectively. Two studies evaluated the Beck Depression Index, and the weighted average was 23.8 (preoperation) and 14.0 (postoperation). Three studies evaluated the Oswestry Disability Index (ODI), and the weighted average was 48.3 (preoperation) and 30.6 (postoperation). Two studies compared burst stimulation with 10-kHz SCS, and both found no difference in back pain scores, whereas both studies found greater improvement in leg pain in the burst groups. Two studies compared low-frequency SCS with 10-kHz SCS, and both studies found no significant difference in VAS or ODI scores between the two treatments. There were no reported unanticipated adverse device effects across the studies.</div></div><div><h3>Conclusion</h3><div>For many patients with refractory PSPS-2, 10-kHz SCS is a safe, effective treatment, but there is a lack of evidence of its superiority to burst or traditional SCS.</div></div>","PeriodicalId":19152,"journal":{"name":"Neuromodulation","volume":"29 1","pages":"Pages 15-25"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145313241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative Effectiveness of Dorsal Root Ganglion and Spinal Cord Stimulation in Chemotherapy-Induced Peripheral Neuropathy: A Single-Center Retrospective Case Series 背根神经节和脊髓刺激治疗化疗引起的周围神经病变的比较效果：单中心回顾性病例系列。

IF 3.5 3区医学 Q2 CLINICAL NEUROLOGY

Neuromodulation

Pub Date : 2026-01-01 DOI: 10.1016/j.neurom.2025.09.314

Gregory Blazek MD , Noushad Mamun DO , Saba Javed MD

Objectives

Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating consequence of many necessary oncologic treatments. Spinal cord stimulation (SCS) is the more common option for refractory cases, but growing evidence suggests dorsal root ganglion stimulation (DRG-S) is another viable option. This study aims to retrospectively compare the use of DRG-S and SCS to determine the modality chosen for permanent implantation for treatment of lower extremity CIPN.

Materials and Methods

This is a retrospective, single-center case series in which five patients with lower extremity CIPN underwent a trial with percutaneous lead placement with an external pulse generator for both modalities. DRG-S was trialed first for five days, followed by a wash-out period of one day; next, SCS was trialed for two to five days.

Treatment-induced neuropathy assessment scale (TNAS) scores were collected for each patient.

Results

A total of five patients with CIPN affecting the lower extremities met the inclusion criteria for this retrospective analysis. All patients presented with bilateral foot pain, with one patient also reporting concomitant lower back pain. The mean duration of CIPN symptoms in this cohort was approximately four years. Mean baseline TNAS score was 56.8, decreasing to 35.8 after the DRG-S trial and to 40.4 after the SCS trial.

Conclusion

Our retrospective case series expands on the growing body of evidence supporting neuromodulation therapies for treatment-refractory chronic CIPN. Specifically, DRG-S indicates a well-tolerated treatment modality with positive clinical outcomes in alleviating isolated CIPN-related pain. Analysis also suggests the need for further research to identify optimal patient selection when considering DRG-S or conventional SCS to treat CIPN.

目的：化疗引起的周围神经病变（CIPN）是许多必要的肿瘤治疗的衰弱性后果。对于难治性病例，脊髓刺激（SCS）是更常见的选择，但越来越多的证据表明背根神经节刺激（DRG-S）是另一种可行的选择。本研究旨在回顾性比较DRG-S和SCS的使用，以确定永久性植入治疗下肢CIPN的方式。材料和方法：这是一个回顾性的单中心病例系列，其中5例下肢CIPN患者接受了两种方式的经皮导线放置和外部脉冲发生器的试验。DRG-S先试验5天，然后是1天的洗脱期；接下来，对SCS进行2 - 5天的试验。收集每位患者的治疗性神经病变评估量表（TNAS）评分。结果：共有5例影响下肢的CIPN患者符合回顾性分析的纳入标准。所有患者均表现为双侧足部疼痛，其中一名患者还报告伴有下背部疼痛。该队列中CIPN症状的平均持续时间约为4年。平均基线TNAS评分为56.8，DRG-S试验后降至35.8，SCS试验后降至40.4。结论：我们的回顾性病例系列扩展了越来越多的证据，支持神经调节疗法治疗难治性慢性CIPN。具体来说，DRG-S是一种耐受性良好的治疗方式，在缓解孤立性cipn相关疼痛方面具有积极的临床结果。分析还表明，在考虑DRG-S或传统SCS治疗CIPN时，需要进一步研究以确定最佳患者选择。

{"title":"Comparative Effectiveness of Dorsal Root Ganglion and Spinal Cord Stimulation in Chemotherapy-Induced Peripheral Neuropathy: A Single-Center Retrospective Case Series","authors":"Gregory Blazek MD , Noushad Mamun DO , Saba Javed MD","doi":"10.1016/j.neurom.2025.09.314","DOIUrl":"10.1016/j.neurom.2025.09.314","url":null,"abstract":"<div><h3>Objectives</h3><div>Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating consequence of many necessary oncologic treatments. Spinal cord stimulation (SCS) is the more common option for refractory cases, but growing evidence suggests dorsal root ganglion stimulation (DRG-S) is another viable option. This study aims to retrospectively compare the use of DRG-S and SCS to determine the modality chosen for permanent implantation for treatment of lower extremity CIPN.</div></div><div><h3>Materials and Methods</h3><div>This is a retrospective, single-center case series in which five patients with lower extremity CIPN underwent a trial with percutaneous lead placement with an external pulse generator for both modalities. DRG-S was trialed first for five days, followed by a wash-out period of one day; next, SCS was trialed for two to five days.</div><div>Treatment-induced neuropathy assessment scale (TNAS) scores were collected for each patient.</div></div><div><h3>Results</h3><div>A total of five patients with CIPN affecting the lower extremities met the inclusion criteria for this retrospective analysis. All patients presented with bilateral foot pain, with one patient also reporting concomitant lower back pain. The mean duration of CIPN symptoms in this cohort was approximately four years. Mean baseline TNAS score was 56.8, decreasing to 35.8 after the DRG-S trial and to 40.4 after the SCS trial.</div></div><div><h3>Conclusion</h3><div>Our retrospective case series expands on the growing body of evidence supporting neuromodulation therapies for treatment-refractory chronic CIPN. Specifically, DRG-S indicates a well-tolerated treatment modality with positive clinical outcomes in alleviating isolated CIPN-related pain. Analysis also suggests the need for further research to identify optimal patient selection when considering DRG-S or conventional SCS to treat CIPN.</div></div>","PeriodicalId":19152,"journal":{"name":"Neuromodulation","volume":"29 1","pages":"Pages 108-114"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145401406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

EV0080 OPTIMIZING THERAPY FOR FACIAL PAIN Ev0080优化面部疼痛治疗

IF 3.5 3区医学 Q2 CLINICAL NEUROLOGY

Neuromodulation

Pub Date : 2026-01-01 DOI: 10.1016/j.neurom.2025.09.080

Khodjimetov Dilshod

引用次数: 0

EV0081 PULSED RADIOFREQUENCY VS. NERVE BLOCKS IN MANAGING POST-STROKE NEUROPATHIC FACIAL PAIN: A COMPARATIVE ANALYSIS Ev0081脉冲射频与神经阻滞治疗脑卒中后神经性面部疼痛的比较分析

IF 3.5 3区医学 Q2 CLINICAL NEUROLOGY

Neuromodulation

Pub Date : 2026-01-01 DOI: 10.1016/j.neurom.2025.09.081

Khodjimetov Dilshod , Ulugbek Asadullaev

引用次数: 0

EV0085 CONTINUOUS SPHENOPALATINE GANGLION STIMULATION FOR REFRACTORY CLUSTER HEADACHE: A SYSTEMATIC REVIEW AND CASE REPORT Ev0085持续蝶腭神经节刺激治疗难治性丛集性头痛：系统回顾和病例报告

IF 3.5 3区医学 Q2 CLINICAL NEUROLOGY

Neuromodulation

Pub Date : 2026-01-01 DOI: 10.1016/j.neurom.2025.09.085

Baraa Dabboucy , Reza Hazrati , Anne-Marie Trudelle , Carl Bouchard , Michel Prudhomme

引用次数: 0

EV0093 REAL-WORLD CLINICAL OUTCOMES USING RADIOFREQUENCY THERMAL ABLATIVE LESIONING FOR USE IN THE TREATMENT OF MOVEMENT DISORDER MOTOR SYMPTOMS Ev0093使用射频热烧蚀损伤用于治疗运动障碍运动症状的实际临床结果

IF 3.5 3区医学 Q2 CLINICAL NEUROLOGY

Neuromodulation

Pub Date : 2026-01-01 DOI: 10.1016/j.neurom.2025.09.093

Andrea Dreyer , Jan Vesper , Erlick Pereira , Rajat Shivacharan , Lilly Chen , Edward Goldberg

引用次数: 0

EV0040 THE MANAGEMENT METHOD OF NATIONAL MULTIPLE SCLEROSIS REGISTRY SYSTEM IN IRAN Ev0040伊朗国家多发性硬化症登记系统管理方法

IF 3.5 3区医学 Q2 CLINICAL NEUROLOGY

Neuromodulation

Pub Date : 2026-01-01 DOI: 10.1016/j.neurom.2025.09.041

Sharareh Eskandarieh, Mohammad Ali Sahraian, Saeideh Ayoubi

引用次数: 0

EV0026 10KHZ SCS REAL-WORLD REVIEW: A RETROSPECTIVE SINGLE-SITE STUDY Ev0026 10khz SCS真实世界回顾：回顾性单点研究

IF 3.5 3区医学 Q2 CLINICAL NEUROLOGY

Neuromodulation

Pub Date : 2026-01-01 DOI: 10.1016/j.neurom.2025.09.027

David Holthouse , Dominic Bailey

引用次数: 0

EV0098 EFFICACY AND SAFETY OF REMOTE DBS PROGRAMMING IN PARKINSON’S DISEASE - INTERIM ANALYSIS FROM THE REMOTE TRIAL 远程DBS编程治疗帕金森病的有效性和安全性——远程试验的中期分析

IF 3.5 3区医学 Q2 CLINICAL NEUROLOGY

Neuromodulation

Pub Date : 2026-01-01 DOI: 10.1016/j.neurom.2025.09.098

Juhi Shaik , Verena Zentsch , Carsten Buhmann , Ute Hidding , Thomas Kinfe , Martin Regensburger , Jost-Julian Rumpf , Alfons Schnitzler , Günter Höglinger , Jan-Hinnerk Mehrkens , Thomas Koeglsperger

引用次数: 0

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Neuromodulation

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀